Hangzhou Just Bio completes $35m series B round

Singaporean government-backed Temasek returned to participate in the medical research company’s latest round.

Hangzhou Just Biotherapeutics has this week announced the close of a $35m series B funding round led by China-based investment firm Hillhouse Capital.

The round was also backed by returning investors Temasek, Lilly Asia Ventures, ARCH Venture Partners, Taikang and BOCGI Zheshang Capital. This brings Hangzhou Just Bio’s lifetime fundraising to over $120m to date.

See more from this Government Report: Singapore


Supporting articles

Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.